Thalidomide in the treatment of leprosy

Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition...

Full description

Saved in:
Bibliographic Details
Published in:Microbes and Infection 2002-09, Vol.4 (11), p.1193-1202
Main Authors: Teo, Steve K., Resztak, Ken E., Scheffler, Michael A., Kook, Karin A., Zeldis, Jerry B., Stirling, David I., Thomas, Steve D.
Format: Article
Language:English
Subjects:
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial diseases
Biological and medical sciences
Drug Therapy, Combination
Erythema Nodosum - drug therapy
Erythema Nodosum - pathology
Erythema nodosum leprosum
Human bacterial diseases
Humans
Incidence
Infectious diseases
Leprostatic Agents - therapeutic use
Leprosy
Leprosy - drug therapy
Leprosy - pathology
Leprosy - transmission
Leprosy, Lepromatous - drug therapy
Leprosy, Lepromatous - pathology
Medical sciences
Models, Molecular
Mycobacterium leprae - pathogenicity
Pharmacology. Drug treatments
Thalidomide
Thalidomide - adverse effects
Thalidomide - pharmacokinetics
Thalidomide - pharmacology
Thalidomide - therapeutic use
Tropical bacterial diseases
Tumor Necrosis Factor-alpha - metabolism
Type 2 reaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-α produced by monocytes.
ISSN:1286-4579
1769-714X
DOI:10.1016/S1286-4579(02)01645-3